Halozyme (HALO) Earnings Dates, Call Summary & Reports

Compare

1,165 Followers

Earnings Data

Report Date

May 12, 2026

After Close (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

1.53

Last Year’s EPS

1.11

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 7 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Feb 17, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call presented strong operational and commercial momentum driven by ENHANZE-enabled blockbusters (DARZALEX SC, PHESGO, VYVGART Hytrulo), significant year-over-year revenue and royalty growth, strategic acquisitions (Hypercon, Surf Bio) that broaden the drug-delivery portfolio and a concrete multi-year growth outlook with robust 2026 guidance. Key near-term headwinds are mostly acquisition-related and one-time (notably a $285M acquired IPR&D charge), higher cost and SG&A items tied to transactions and litigation, and ongoing IP/legal proceedings that add uncertainty. Management highlighted a clear strategic roadmap (ENHANZE expansion, Hypercon pipeline, auto-injectors, ADC opportunity) and expects deleveraging and continued expansion of the product portfolio into the late 2020s and 2030s.

Company Guidance

Halozyme reiterated 2026 guidance calling for total revenue of $1.71–$1.81 billion (up 22%–30% YoY), royalty revenues of $1.13–$1.17 billion (up 30%–35% YoY), adjusted EBITDA of $1.125–$1.205 billion (which includes ~ $60 million of Hypercon/Surf Bio investment), and non‑GAAP diluted EPS of $7.75–$8.25 (does not assume future share repurchases). They expect Q1 royalty revenue to be ~5%–10% below Q4 2025 with quarterly sequential growth thereafter, and total revenue to decline Q4→Q1 due to no planned Q1 milestones (milestones weighted to H2). Operationally, Halozyme plans to support six new ENHANZE and two Hypercon programs entering Phase I in 2026 (bringing the development portfolio to 15 products, 13 with ENHANZE), intends to deliver at least three new licensing deals (1–3 ENHANZE, 1–2 Hypercon), and expects to deleverage from 2.1x net debt/EBITDA at year‑end 2025 (ex‑IPR&D) to below 1x by end‑2026.

Record Full-Year Revenue Growth

Total revenue grew 38% year-over-year to $1.4 billion for FY2025, driven primarily by ENHANZE momentum and product sales.

Royalty Revenue Surge

Total royalty revenue increased 52% year-over-year to $867.8 million, reflecting strong uptake of ENHANZE-enabled products (notably DARZALEX SC, VYVGART Hytrulo and PHESGO).

DARZALEX Subcutaneous Franchise Performance

Johnson & Johnson reported DARZALEX total sales up 22% operationally to $14.4 billion in 2025; Halozyme recognized $483 million in royalties (up 29% year-over-year). DARZALEX SC represents 97% share of U.S. sales and sales are projected to exceed $18 billion by 2028.

PHESGO and VYVGART Hytrulo Strong Growth

PHESGO sales rose 48% YoY to CHF 2.4 billion (~$3.0 billion), generating $105.6 million in royalties (+51% YoY). VYVGART and VYVGART Hytrulo grew 90% YoY to $4.15 billion, producing $157.2 million in royalties (444% YoY growth).

Accelerated Product Approvals and Expanded Blockbuster Set

Multiple regulatory milestones: DARZALEX FASPRO approval for smoldering multiple myeloma, new J&J approval for newly diagnosed multiple myeloma (fifth indication for newly diagnosed; 12th overall), and RYBREVANT SC approvals in U.S., Japan and China. Management now cites 10 ENHANZE-enabled global blockbuster opportunities.

Portfolio Expansion via Acquisitions

Expanded from 2 to 4 subcutaneous drug delivery technologies through acquisition of Elektrofi (Hypercon) and Surf Bio (hyperconcentration), both with long-duration IP into the mid-2040s, broadening capabilities (ENHANZE, auto-injectors, Hypercon, Surf Bio).

Hypercon Development and Longer-Term Revenue Opportunity

Three Hypercon partnerships in place with plans to advance 2 programs into Phase I by end of 2026; first approvals projected in 2030–2031. Management projects ~ $1 billion in Hypercon royalty revenue within five years of first launches in the mid-2030s.

ENHANZE Pipeline and Clinical Momentum

Guidance for 2026 includes supporting 6 new ENHANZE programs entering Phase I (bringing development portfolio to 15 products, 13 with ENHANZE) and expectation to add 1–3 new ENHANZE agreements — giving line of sight to royalty contributions beginning ~2029.

Preclinical ADC Data Indicating Potential Clinical Benefit

Preclinical data for two ADCs showed improved injection-site clearance (24-hour injection-site reduction: 87% for ADC1 and >50% for ADC2 with ENHANZE) and lower serum Cmax versus IV (Cmax reductions of 75% for ADC1 and 61% for ADC2). Modeling suggests subcutaneous dosing with ENHANZE could achieve equal/higher overall exposure with lower peak concentrations, implying potential improved benefit/risk.

Balance Sheet Strengthening and 2026 Financial Guidance

Issued $750M 2031 and $750M 2032 convertible notes, repurchased portions of 2027/2028 notes and upsized revolving credit to $750M; reported net debt/EBITDA of 2.1x (excluding acquired IPR&D) with expectation to delever below 1x by end of 2026. Reiterated 2026 guidance: total revenue $1.71B–$1.81B (+22%–30% YoY), royalty revenue $1.13B–$1.17B (+30%–35% YoY), adjusted EBITDA $1.125B–$1.205B, and non-GAAP diluted EPS $7.75–$8.25.

Quarterly Momentum

Q4 2025 total revenue increased 52% sequentially to $451.8 million; Q4 royalty revenue was $258 million (+51% YoY).

Halozyme (HALO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HALO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 12, 2026	2026 (Q1)	1.53 / -	1.11	―	―	―
Feb 17, 2026	2025 (Q4)	2.20 / -0.24	1.26	-119.05% (-1.50)
Nov 03, 2025	2025 (Q3)	1.63 / 1.72	1.27	35.43% (+0.45)
Aug 05, 2025	2025 (Q2)	1.27 / 1.54	0.91	69.23% (+0.63)
May 06, 2025	2025 (Q1)	0.95 / 1.11	0.79	40.51% (+0.32)
Feb 18, 2025	2024 (Q4)	1.16 / 1.26	0.82	53.66% (+0.44)
Oct 31, 2024	2024 (Q3)	0.99 / 1.27	0.75	69.33% (+0.52)
Aug 06, 2024	2024 (Q2)	0.76 / 0.91	0.74	22.97% (+0.17)
May 07, 2024	2024 (Q1)	0.69 / 0.79	0.47	68.09% (+0.32)
Feb 20, 2024	2023 (Q4)	0.82 / 0.82	0.42	95.24% (+0.40)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

HALO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 17, 2026	$80.48	$73.23	-9.01%
Nov 03, 2025	$66.20	$68.05	+2.79%
Aug 05, 2025	$60.81	$62.32	+2.48%
May 06, 2025	$59.38	$70.14	+18.12%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Halozyme Therapeutics (HALO) report earnings?

Halozyme Therapeutics (HALO) is schdueled to report earning on May 12, 2026, After Close (Confirmed).

What is Halozyme Therapeutics (HALO) earnings time?

Halozyme Therapeutics (HALO) earnings time is at May 12, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is HALO EPS forecast?

HALO EPS forecast for the fiscal quarter 2026 (Q1) is 1.53.